Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Svetlana Trestman

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Acta Haematologica|March 30, 2025
Acquired FX Deficiency in Multiple Myeloma without Concomitant Amyloidosis: A Rare Case ReportRoi Gat, Svetlana Trestman, Ilya Kirgner
Leukemia & Lymphoma|February 13, 2004
Autoimmune thrombocytopenia in chronic myeloid leukemia treated with interferon-alpha: differential diagnosis and possible pathogenesisYair Herishanu, Svetlana Trestman, Ilya Kirgner, et al.
European Journal of Haematology|October 26, 2023
Treatment with low-dose, single-agent belantamab mafodotin is safe and provides long-term responses in heavily pretreated multiple myeloma patientsIrit Avivi, Tamir Shragai, Efrat Luttwak, et al.
The Israel Medical Association Journal : IMAJ|December 16, 2015
Bone Marrow-Related SyncopeHaim Shmilovich, Svetlana Trestman, Stella Bak, et al.
European Journal of Internal Medicine|February 14, 2004
Low-dose interferon-alpha accelerates atherosclerosis in an LDL receptor-deficient mouse modelZohar Levy, Rita Rachmani, Svetlana Trestman, et al.
European Journal of Haematology|March 4, 2020
Bortezomib washout duration prior to stem cell mobilization in patients with newly diagnosed multiple myelomaEfrat Luttwak, Odelia Amit, Irit Avivi, et al.
Cancers|October 16, 2024
The Outcome of Octogenarian Patients with Multiple Myeloma Treated Outside Clinical Studies, Focusing on Tolerability and Efficacy of TreatmentDana Amsterdam, Ori Grossberger, Natan Melamed, et al.
International Journal of Experimental Diabesity Research|May 15, 2003
Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabetic low-density lipoprotein receptor-deficient miceZohar Levy, Ayana Dvir, Aviv Shaish, et al.
BMC Cancer|June 1, 2020
Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myelomaEfrat Markus, Svetlana Trestman, Yael Cohen, et al.
Leukemia & Lymphoma|January 19, 2019
Impaired lymphocyte reconstitution after autologous transplant is associated with apoptosis of CD8+ T cells and adverse clinical outcomeUri Rozovski, Ella Naparstek, Shani Frank, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Acta Haematologica|March 30, 2025
Acquired FX Deficiency in Multiple Myeloma without Concomitant Amyloidosis: A Rare Case ReportRoi Gat, Svetlana Trestman, Ilya Kirgner
Leukemia & Lymphoma|February 13, 2004
Autoimmune thrombocytopenia in chronic myeloid leukemia treated with interferon-alpha: differential diagnosis and possible pathogenesisYair Herishanu, Svetlana Trestman, Ilya Kirgner, et al.
European Journal of Haematology|October 26, 2023
Treatment with low-dose, single-agent belantamab mafodotin is safe and provides long-term responses in heavily pretreated multiple myeloma patientsIrit Avivi, Tamir Shragai, Efrat Luttwak, et al.
The Israel Medical Association Journal : IMAJ|December 16, 2015
Bone Marrow-Related SyncopeHaim Shmilovich, Svetlana Trestman, Stella Bak, et al.
European Journal of Internal Medicine|February 14, 2004
Low-dose interferon-alpha accelerates atherosclerosis in an LDL receptor-deficient mouse modelZohar Levy, Rita Rachmani, Svetlana Trestman, et al.
European Journal of Haematology|March 4, 2020
Bortezomib washout duration prior to stem cell mobilization in patients with newly diagnosed multiple myelomaEfrat Luttwak, Odelia Amit, Irit Avivi, et al.
Cancers|October 16, 2024
The Outcome of Octogenarian Patients with Multiple Myeloma Treated Outside Clinical Studies, Focusing on Tolerability and Efficacy of TreatmentDana Amsterdam, Ori Grossberger, Natan Melamed, et al.
International Journal of Experimental Diabesity Research|May 15, 2003
Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabetic low-density lipoprotein receptor-deficient miceZohar Levy, Ayana Dvir, Aviv Shaish, et al.
BMC Cancer|June 1, 2020
Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myelomaEfrat Markus, Svetlana Trestman, Yael Cohen, et al.
Leukemia & Lymphoma|January 19, 2019
Impaired lymphocyte reconstitution after autologous transplant is associated with apoptosis of CD8+ T cells and adverse clinical outcomeUri Rozovski, Ella Naparstek, Shani Frank, et al.
Pageof 3